Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients

Matthias Bache1*, Matthias Kappler1, Henri Wichmann1, Swetlana Rot1, Antje Hahnel1, Thomas Greither2, Harun M Said3, Matthias Kotzsch4, Peter Würl5, Helge Taubert2, Dirk Vordermark1

Abstract

Background: Osteopontin (OPN) overexpression is correlated with a poor prognosis for tumor patients. However, only a few studies investigated the prognostic impact of expression of OPN in soft tissue sarcomas (STS) yet.

Methods: This study is based on tumor and serum samples from 93 adult STS patients. We investigated OPN protein levels in serum (n = 86) and tumor tissue (n = 80) by ELISA and OPN mRNA levels in tumor tissue (n = 68) by quantitative real-time PCR.

Results: No correlation was found between OPN levels in serum and tumor tissue. Moreover, an elevated OPN protein level in the serum was significantly associated with clinical parameters such as higher stage (p = 0.004), higher grade (p = 0.003), subtype (p = 0.002) and larger tumor size (p = 0.03). OPN protein levels in the tumor tissue were associated with higher stage (p = 0.06), higher grade (p = 0.003), subtype (p = 0.07) and an increased rate of relapse (p = 0.02). In addition, using a Cox’s proportional hazards regression model, we found that an elevated OPN protein level in the serum and tumor tissue extracts is a significant negative prognostic factor for patients with STS. The relative risks of tumor-related death were 2.2 (p < 0.05) and 3.7 (p = 0.01), respectively.

Conclusion: Our data suggest OPN protein in serum as well as in tumor tissue extracts is an important prognostic factor for soft tissue sarcoma patients.

Background

OPN, a phosphorylated glycoprotein, is detected in body fluids as well as in tumor tissues. Initially, it was suggested that OPN is expressed by macrophages infiltrating the tumor rather than by tumor cells themselves [1]. However, elevated serum or plasma levels of OPN have been detected in a variety of human cancers, which has been correlated with tumor progression and metastasis [2-4]. Moreover, tumor OPN protein over expression is also linked to a worse prognosis in different tumor entities such as breast cancer [5,6], lung cancer [7], cervical cancer [8,9], prostate cancer [10] and head and neck cancer [11-13]. Furthermore, previous studies suggest that high tumor OPN mRNA expression also correlates with an unfavorable prognosis [14-18].

In support of its prognostic value, direct or indirect inhibition of the OPN signaling pathway results in reduced malignant tumor potential with effects on cell survival, migration, invasion, tumor growth and metastasis (reviewed in [4,19,20]). However, only a few studies have investigated the role of osteopontin in tumor progression of sarcoma patients. For example, in primary sarcomas of the pulmonary artery, OPN protein could be detected in tumor cells and in macrophages and it is potentially involved in tumor progression and metastasis [21]. A further immunohistochemical study of STS showed that OPN in tumor tissue is associated with tumor stage, grade and overall survival of STS patients at 5-years [22]. However, another study using immunohistochemical evaluation of OPN expression did not provide predictive information on the outcome of osteosarcoma patients [23]. We therefore analyzed OPN mRNA and protein levels of tumor samples and OPN
serum levels of 93 histological verified adult STS patients. Moreover, to characterize the role of OPN in soft tissue sarcoma, we correlated OPN levels with clinical parameters and prognosis.

**Methods**

**Patients and tumor material**

Tumor tissue and serum samples of 93 adult patients with histologically verified primary STS were analyzed (Table 1). In detail, we have analyzed OPN protein levels in serum (86 patients) and tumor tissue (80 patients) and OPN mRNA level in tumor tissue (68 patients). Patients and tissue samples have been partially described previously [24-26]. The study was carried out in compliance with the Helsinki Declaration and it was approved by the Ethics Committee of the Medical Faculty of the University Halle. All patients gave written informed consent (Institute of Pathology, University of Halle, Germany and Department of Surgery 1, University of Leipzig, Germany). Patients' mean age was 56 years (19 to 87 years). The median follow-up time was 44 months (2 to 146 months). The overall survival according to stage was 86% for stage I (n = 15), 59% for stage II (n = 39), 37% for stage III (n = 19) and 0% for stage IVa (n = 9). Tumor tissue was collected following surgical resection and snap-frozen in liquid nitrogen. Tumors were classified according to the van Unnik grading system [27].

**Reverse transcription-polymerase chain reaction and real-time quantitative PCR**

Total RNA was isolated using the RNeasy Mini Kit according to the manufacturer’s instructions (Qiagen, Hilden, Germany). Subsequently, 1000 ng of RNA was reverse transcribed with random hexamer primers and Superscript II reverse transcriptase (Invitrogen,

| Table 1 Histopathological and clinical data in soft tissue sarcoma patients |
|---------------------------------|----------------|----------------|----------------|
|                                 | Serum OPN protein | Tumor OPN protein | Tumor OPN mRNA |
| Total                           | 86             | 80             | 68             |
| **Tumor stage**                 |                |                |                |
| I                               | 14             | 13             | 12             |
| II                              | 37             | 32             | 26             |
| III                             | 26             | 26             | 22             |
| IV                              | 9              | 9              | 8              |
| **Tumor type**                  |                |                |                |
| LS                              | 21             | 21             | 18             |
| FS and MFH                      | 24             | 20             | 17             |
| NS                              | 8              | 7              | 3              |
| RMS and LMS                     | 22             | 22             | 20             |
| Other STS                       | 11             | 10             | 10             |
| **Irradiation**                 |                |                |                |
| Yes                             | 31             | 32             | 29             |
| No                              | 55             | 48             | 39             |
| **Chemotherapy**                |                |                |                |
| Yes                             | 8              | 7              | 5              |
| No                              | 78             | 73             | 63             |
| **Tumor size**                  |                |                |                |
| T1                              | 12             | 11             | 10             |
| T2                              | 74             | 69             | 58             |
| **Tumor resection**             |                |                |                |
| Radical (R0)                    | 57             | 54             | 49             |
| Not Radical (R1)                | 29             | 26             | 19             |
| **Distant metastases**          |                |                |                |
| M0                              | 79             | 73             | 62             |
| M1                              | 7              | 7              | 6              |
| **Relapse**                     |                |                |                |
| Yes                             | 55             | 51             | 47             |
| No                              | 31             | 29             | 21             |

Abbreviations: OPN: osteopontin, LS: liposarcoma, MFH: malignant fibrous histiocytoma, FS: fibrosarcoma; NS: neurogenic sarcoma; LMS: leiomyosarcoma; RMS: rhabdomyosarcoma; STS: soft tissue sarcoma;
Karlsruhe, Germany). The cDNA synthesis was performed as described previously [28]. The mRNA levels of OPN and the housekeeping gene, hypoxanthin phosphoribosyl-transferase (HPRT), were quantified using Quantitect SYBRGreen PCR kit (Qiagen, Hilden, Germany) in a Rotorgene 3000 thermal cycler (LTFAbionik, Wassenburg, Germany). The OPN and HPRT transcripts were amplified with primer pairs of Table 2. The PCR cycling conditions included incubation for 15 min at 95°C, followed by 40 cycles of 30 sec at 95°C, 30 sec at 60°C and 30 sec at 72°C. A melting curve analysis in a range from 65°C to 95°C (5°C/sec) was appended. OPN mRNA was quantified as molecules of OPN mRNA/pg HPRT mRNA.

### OPN-ELISA measurements

Tumor tissue extracts were prepared from frozen tissues using a standard extraction protocol. Briefly, 20 slices of 10 μm thickness were cut. The total protein was extracted by solubilizing the tissues in 1 ml Giordano buffer using sonication on ice. The cell lysates were clarified by centrifugation at 15000 rpm for 15 min. The protein content was determined using the Bradford assay. Fresh blood samples collected before surgical treatment were coagulated for 20 min at room temperature and centrifuged at 3000 rpm for 10 min (Sarstedt monovette, Nümbrecht, Germany). The serum and tumor tissue extracts were aliquoted and stored at -80°C until analysis. Aliquots of each sample were analyzed in duplicate using a commercial ELISA system for OPN (IBL International, Hamburg, Germany) according to the manufacturer’s instructions [3].

### Statistical methods

All statistical analyses were performed with the SPSS software package 16.0 for Windows (SPSS Inc., Chicago, IL). The differences in the numerical data between two groups were evaluated using the Pearson’s test or Fisher’s exact test. For survival analyses the overall survival of STS patients was used as follow-up endpoint. The survival curves were generated using Kaplan-Meier analysis and the log rank test was used to test for differences. For univariate and multivariate analyses (adjusted to tumor stage) the Cox’s proportional hazard regression model was used to calculate the hazard ratio in the analysis of survival. A p-value of less than 0.05 was considered to be statistically significant.

### Results

#### Osteopontin levels in serum and tumor tissue

In patients with soft tissue sarcoma (STS) the median protein concentration of OPN in the serum and tumor tissue extracts was 704 ng/ml (184-2660 ng/ml) and 51.9 ng/mg (3.2-868 ng/mg), respectively (Fig. 1). The median OPN/HPRT transcript level ratio was 12.8 molecules OPN/pg HPRT (with a range of 0-110 molecules OPN/pg HPRT, Fig. 1). In particular, there was no correlation between OPN mRNA and OPN protein levels of tumors (n = 66; p = 0.4), serum and tumor OPN protein levels (n = 73; p = 0.9) or tumor OPN mRNA and serum OPN protein levels (n = 62; p = 0.7).

#### Osteopontin levels and survival analyses

In subgroups split at the median serum or tumor OPN protein level, there was no significant difference in overall survival. However, when specimens were divided into four groups according to their OPN protein levels, the serum and tumor OPN protein levels did associate with different clinical parameters and overall survival. The group with the lowest tumor (≤ 34.34 ng/mg) or serum (≤ 516.54 ng/ml) OPN protein levels, i.e., the lowest quartile, had a favorable outcome compared to the other three groups (Table 3).

Kaplan-Meier analyses showed a significant decrease of overall survival for the three groups with high OPN protein levels compared to the group with the lowest tumor (p = 0.007; log-rank test) and serum (p = 0.04; log-rank test) OPN protein levels. The mean survival time of the patient group with the lowest OPN protein level was 103 months (serum) and 68 months (tumor) whereas patients of the three remaining groups (high OPN protein levels) survived on average 60 months and 58 months (for serum and tumor tissue OPN protein levels, respectively). In addition, patients with both high serum and high tumor OPN protein levels had the worst prognosis (data not shown). Using a univariate Cox regression hazard model for STS patients with high OPN protein level in the serum or in tumor tissue extracts, the risk of tumor-related death was a 2.2 (95% confidence interval (CI) 1.01-5.1; p < 0.05) and 3.7 (95% confidence interval (CI) 1.3-10.4; p = 0.01), respectively (Fig. 2, Table 3). However, in a multivariate Cox’s regression hazard model adjusted to tumor stage OPN protein level was not significantly correlated with prognosis.

#### Bivariate analysis of osteopontin levels with clinical parameters

Bivariate analysis of OPN expression did show an association of serum and tumor OPN protein levels with

| Table 2 Primer sequences and primer locations applied for qRT-PCR |
|---|---|---|---|---|
| gene | primer | sequence 5’ → 3’ | Localization |
| HPRT | sense | 5’-TGCTGACCTGGATTAC-3’ | 309-328 |
| HPRT | antisense | 5’-CCGGACCTGACCATCTT-3’ | 551-570 |
| OPN | sense | 5’-TGGCGAGGTGATGTG-3’ | 555-573 |
| OPN | antisense | 5’-CGGGGATGGCGCAGTTGATG-3’ | 686-703 |
different clinical parameters. In particular, high serum OPN protein levels correlated with high tumor stage ($p = 0.004$), grade of tumors ($p = 0.003$) and tumor size ($p = 0.03$). Additionally, all patients with early distant metastasis (7/86) had a high median serum OPN protein level of 1301 ng/ml (1009 to 2660 ng/ml) compared to patients without distant metastasis (79/86) who had a median serum OPN protein level of 657 ng/ml (183 to 1873 ng/ml). However, the difference was not significant (Table 3). A high tumor OPN protein level was significantly related to tumor grade ($p = 0.003$) and an increased rate of relapse ($p = 0.02$), and also showed a trend association with high tumor stage ($p = 0.06$) (Table 3). Furthermore, plasma OPN protein levels significantly correlated with tumor type ($p = 0.002$) whereas tumor OPN protein levels displayed only a trend association with tumor type ($p = 0.07$). Moreover, the patient group with the lowest serum and tumor OPN protein level was composed of 57% and 48% liposarcoma patients, respectively. In contrast, the three remaining patient groups with a high serum (>516.54 ng/ml) and tumor (>34.34 ng/mg) OPN protein level were composed of more than 80% of patients with malignant fibrous histiocytoma (MFH), fibrosarcoma (FS), leiomyosarcoma (LMS), rhabdomyosarcoma (RMS). In contrast to protein expression, statistical analysis of OPN mRNA levels showed no association with clinical parameters or clinical outcome (Table 3).

Discussion

OPN overexpression is linked to an unfavorable prognosis in a variety of human cancers. However, only a few studies to date have investigated the prognostic impact of osteopontin in sarcoma patients. In the present study, we analyzed OPN mRNA and protein levels in tumors and the OPN protein levels from the serum of 93 soft tissue sarcoma patients and correlated OPN levels with clinical parameters and prognosis.

In our study no correlation was found between OPN levels in serum and tumor tissue. It is well known that extracellular OPN is involved in tumor progression with signaling to proliferation, migration and survival. Also intracellular OPN is involved in cell migration [29]. Additionally, there is also evidence that suggests that intracellular OPN has other cellular functions, particularly in relation to cell proliferation [30]. But regulation between intra- and extracellular OPN forms remains unknown. Nordmark et al. (2007) assume a relation between plasma concentration of OPN and intratumoral OPN production [31]. However, in agreement with our

![Figure 1](http://www.biomedcentral.com/1471-2407/10/132)
results Nordmark et al. (2007) detected no correlation between plasma OPN and tumor OPN protein levels in patients with head and neck cancer (p = 0.75). Furthermore, own in vitro studies detected a clear decrease of extracellular OPN protein levels after transfection with OPN siRNA in MDA-MB231 cells. In contrast, the intracellular OPN protein level was only partially decreased (Hahnel et al., manuscript submitted). More studies on the functions of intracellular OPN forms are necessary to understand their relationship with extracellular OPN and their tumor biological role.

Our data suggest that increased serum and tumor OPN protein levels are significantly associated with clinical parameters, such as tumor stage, tumor grade, subtype of tumor, tumor size and the rate of relapse (Table 3). In the Kaplan-Meier analysis, a significantly decreased overall survival was observed for patients with strong OPN protein expression in their serum (p = 0.04; Table 3) and tumor tissue (p = 0.007; Table 3). Furthermore, the univariate Cox’s regression hazard model demonstrated that STS patients with a high serum and tumor OPN protein level have an increased risk of tumor-related death of 2.2 (p < 0.05) and 3.7 (p = 0.01; Fig. 2), respectively (Table 3). This is in agreement with a previously reported immunohistochemical study of 33 soft tissue sarcoma patients that showed an increased OPN level significantly correlated with higher tumor stage, grade and overall survival [22]. Furthermore, primary sarcomas of the pulmonary artery display an abundant immunohistochemical OPN protein staining of tumor cells and extracellular matrix. Therefore, OPN protein may play a substantial role in tumor progression of vessel sarcomas [21]. However, an immunohistochemical OPN study did not find any correlation

| Table 3 Association of serum and tumor OPN levels with clinical parameters in soft tissue sarcoma patients |
|----------------------------------------------|--------------------------------|--------------------------------|
| Category                               | Serum OPN protein level | Tumor OPN protein level | Tumor OPN mRNA level in |
|                                         | in ng/ml ≤ 516.54       | in ng/ml ≤ 34.34        | molecules/pg HPRT ≤ 0.576 |
| Total                                   | 21                      | 20                      | 17                           |
| Tumor stage                             | p = 0.004*              | p = 0.06                | p = 0.21                     |
| I                                       | 8                       | 7                       | 5                             |
| II                                      | 10                      | 7                       | 25                            |
| III                                     | 2                       | 4                       | 22                            |
| IV                                      | 1                       | 2                       | 7                             |
| Tumor type                              | p = 0.002*              | p = 0.07                | p = 0.19                      |
| LS                                      | 12                      | 10                      | 5                             |
| FS+MFH                                  | 4                       | 3                       | 6                             |
| NS                                      | 0                       | 2                       | 2                             |
| RMS+LMS                                 | 3                       | 4                       | 3                             |
| Other STS                               | 2                       | 1                       | 1                             |
| Tumor size                              | p = 0.03*               | p = 0.85                | p = 0.24                      |
| T1                                      | 6                       | 3                       | 1                             |
| T2                                      | 15                      | 17                      | 16                            |
| Distant metastasis                      | p = 0.12                | p = 0.82                | p = 0.14                      |
| M0                                      | 21                      | 18                      | 17                            |
| M1                                      | 0                       | 2                       | 5                             |
| Relapse                                 | p = 0.41                | p = 0.02*               | p = 0.88                      |
| R0                                      | 15                      | 17                      | 12                            |
| R1                                      | 6                       | 3                       | 5                             |
| Follow-up                               | Alive                   | 16                      | 11                            |
| Dead                                    | 7                       | 4                       | 6                             |
| Kaplan-Meier analysis                   | p = 0.04*               | p = 0.007*              | p = 0.2                       |
| mean survival in months                 | 103                     | 68                      | 72                            |
| Cox’s-Regression model                  | p < 0.05*               | p = 0.01*               | p = 0.21                      |
| RR                                      | 2.2                     | 3.7                     | 1.7                           |
| CI                                      | 1.0-5.1                 | 1.3-10.4                | 0.7-4.3                       |

p* value was significant, when p < 0.05. Abbreviations: OPN: osteopontin, LS: liposarcoma, MFH: malignant fibrous histiocytoma; FS: fibrosarcoma; NS: neurogenic sarcoma; LMS: leiomyosarcoma; RMS: rhabdomyosarcoma; STS: soft tissue sarcoma; RR: relative risk of tumor-related death; CI: confidence interval of tumor-related death.
between OPN protein expression and outcome of osteosarcoma patients [23]. In this regard, Luo et al. were able to show that different osteosarcoma cell lines had significantly lower OPN levels than mature osteoblasts [32]. This may indicate that OPN has no significance for osteosarcoma tumor growth. However, antisense oligodeoxynucleotides against human OPN reduced the tumorigenicity of xenotransplanted osteosarcoma tumors in nude mice [33]. Additionally, our analysis shows that siRNA-induced osteopontin inhibition results in reduced clonogenic survival and migration of soft tissue sarcoma and breast cancer cell lines (Hahnel et al., manuscript submitted).

Our analysis of tumor OPN mRNA expression of 68 soft tissue sarcoma patients did not show any association with clinical parameters or prognosis. In contrast, another study of 41 osteosarcoma patients did show that a high OPN mRNA level is correlated with overall survival, event-free survival and relapse-free survival [34]. Moreover, a study of 15 adult soft tissue sarcoma patients showed a significant increase of OPN mRNA levels compared to normal tissue [22]. In addition, OPN splice variants may be involved in tumor progression. In particular, osteopontin-c has been postulated to be a significant factor for glioma [35], breast cancer [17,36] and hepatocellular carcinoma [37]. Clearly, more data are needed to characterize the role of osteopontin mRNA in sarcomas.

Conclusion
In the present study, we analyzed OPN mRNA and protein levels in tumors and the OPN protein levels from the serum of 93 soft tissue sarcoma patients. Our data suggest that increased serum and tumor OPN protein levels are significantly associated with clinical parameters, such as tumor stage, tumor grade, subtype of tumor, tumor size and the rate of relapse. In addition, using a univariate Cox’s proportional hazards regression model, we found that an elevated OPN protein level in the serum and tumor tissue extracts is a significant negative prognostic factor for patients with STS. Our data suggest OPN protein in serum as well as in tumor tissue extracts is an important prognostic factor for soft tissue sarcoma patients.

Acknowledgements
This work was supported by the Wilhelm Sander Stiftung (grant number: 2007.123.1). We thank our colleagues from the Department of Radiotherapy, the University of Halle, for their contribution and continuous support on this study. We thank Astrid Katzer from the University of Würzburg for her excellent technical assistance as well. Helge Taubert was supported by the Deutsche Krebshilfe (grant number: 107590).

Author details
1Department of Radiotherapy, Martin-Luther-University Halle-Wittenberg, Halle, Germany. 2Department of Oral and Maxillofacial Plastic Surgery, Martin-Luther-University Halle-Wittenberg, Halle, Germany. 3Radiation Oncology, University of Würzburg, Würzburg, Germany. 4Institute of Pathology, Dresden University of Technology, Dresden, Germany. 5Department of Surgery, Malteser St Franziskus Hospital gGmbH, Flensburg, Germany.
Authors’ contributions
MB and DV designed the study, collected data, performed statistical analysis and drafted the manuscript. MGa, HW, SR, AH, TG, HMs and Mtko and HT made substantial contributions acquisition of data, and analysis and interpretation of data. PW treated the patients, collected material and data and reviewed the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 13 October 2009 Accepted: 8 April 2010
Published: 8 April 2010

References
1. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001, 1:621-632.
2. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R.
3. Tutk AB, Oktar A, Kusht T, Hansgen G, Dunct J, Flenit M.
4. Bache M. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critical on the choice of ELISA system. BACAM 2006, 6:207.
5. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008, 27:103-118.
6. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998, 76:502-508.
7. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002, 62:3417-3427.
8. BoldivLI, Domeni V, Dell'Omogol M, Prati MC, Favisana P, Camacci T, Lucchi M, Mussia A, Santoro M, Basolo F, Fontanini G. Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 2005, 93:453-457.
9. Sakaguchi H, Fujimoto J, Hong BI, Tamura T. Clinical implications of osteopontin in metastatic lesions of uterine cervix cancers. Cancer Lett 2007, 247:98-102.
10. Cho H, Hong SW, Oh YJ, Kim MA, Kang ES, Lee JM, Kim SW, Kim SH, Kim JH, Kim YT, Lee K. Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol 2006, 134:909-917.
11. Forootan SS, Foster CS, Aacht VR, Adamson J, Smith PH, Lin K, Ke Y. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006, 118:225-2261.
12. Bache M, Reddremann R, Said HM, Holzhausen HJ, Taubert H, Becker A, Kusht T, Hansgen G, Dunct J, Vordermark D. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys 2006, 66:1481-1487.
13. Celletti A, Testa D, Stabano S, Merolla F, Guariano V, Castellone MD, Iovine R, Mansueto G, Somma P, De Rosa G, Galli V, Melillo RM, Santoro M. Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin Cancer Res 2005, 11:8019-8027.
14. Chen CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CM, Chen CH, Huang CC. Clinical significance of osteopontin expression in T1 and T2 tongue cancers. Head Neck 2008, 30:776-781.
15. Schneider S, Yoshim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Hölscher AH, Danenberg PV. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 2004, 10:1588-1596.
16. Kolb A, Kleef J, Ouvriehli A, Espostio I, Giuse NA, Adwan H, Giase T, Bütchler MW, Berger MR, Friess H. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther 2005, 4:740-746.
17. Higashiyama M, Ito T, Tanaka E, Shimada Y. Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol 2007, 14:3419-3427.
18. Mirza M, Shaugnessy E, Hurley JK, Vanpatten KA, Pesano GA, He B, Weber GF. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008, 122:889-897.
19. Patani N, Jshr FA, Jiang W, Mokbel K. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 2008, 28(6):1405-1411.
20. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 2001, 1552:61-85.
21. Jain S, Chachobry G, Bulbul A, Kaur R, Kuyd GG. Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets 2007, 11:81-90.
22. Gaumann A, Petrow V, Mentzel T, Mayer E, Darm H, Otto M, Kirkpatrick CJ, Kriegsmann J. Osteopontin expression in primary sarcomas of the pulmonary artery. Virchows Arch 2001, 439:656-674.
23. Bramwell VH, Tuck AB, Wilson SM, Sttt LW, Cherian AK, Roke SC, Al-Kath W, Postenka CO, Chambers AF. Expression of osteopontin and HGF/EGF in adult soft tissue tumors. Cancer Biol Ther 2005, 4:1336-1341.
24. Würfl P, Fittlau M,meye A, Bartel F, Schmidt H, Schonfelder M, Taubert H. Low detection rate of p53 antibodies in sera of soft tissue sarcoma patients. Cancer Lett 2001, 17:199-205.
25. Würfl P, Kappeler M,meye A, Bartel F, Köhler T, Latetschrager C, Bache M, Schmidt H, Taubert H. Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Cancer 2002, 129:943-949.
26. Taubert H, Würfl P, Grethier T, Kappeler M, Bache M, Bartel F, Kehen A, Latetschrager C, Harris LC, Kaushal D, Fussel S, Mey A, Böhne K, Schmidt H, Holzhausen HJ, Hauptmann S. Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients. Oncogene 2007, 26:7170-7174.
27. van Urmik JA, Coindre JM, Contesso C, Albus-Lutter CE, Schott D, Sylvester R, Thomas D, Bramwell V, Mouridsen HT. Grading of Soft Tissue Sarcomas: Experience of the EORTC Soft and Bone Sarcoma Group. Eur J Cancer 1993, 29:2089-2093.
28. Kappeler M, Kotzsch M, Bartel F, Fussel S, Lautetschrager C, Schmidt U, Würfl P, Bache M, Schmidt H, Taubert H. Elevated expression rate of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res 2003, 9:1089-1104.
29. Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA, Sodek J. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 2003, 184:118-130.
30. Jundaid A, Moon CC, Harding GE, Zeradika P. Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am J Phys Cell Physiol 2007, 292:C919-29.
31. Nordmark M, Eriksen JG, Gestbl V, Alpers H, Horasan MR, Overgaard J. Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 2007, 83:389-397.
32. Luo X, Chen J, Song WX, Tang N, Luo J, Deng ZL, Sharp A, He G, Bi Y, He BC, Bennett E, Huang J, Kang Q, Jiango W, Su Y, Zhu GH, Yin H, He Y, Wang Y, Song SJ, Chen L, Zhuo GW, Mentag A, Reid RR, Haydon RC, Luu HH, He TC. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest 2008, 88:1264-1277.
33. Liu SJ, Zhang DI, Xu XM, Zhang L, Cai ZW, Sun LQ, Liu YJ, Xue Y, Hu GF. The inhibition of in vivo tumorigenesis of osteosarcoma (OS-732 cells by antitumor human osteopontin RNA. Cell Mol Biol Lett 2008, 13:11-19.
34. Dalla-Torre CA, Yoshimoto M, Lee CH, Joshua AM, de Toledo SR, Pethilli AS, Andrade J, Chilton-MacNeil F, Zielenis M, Shakte MA. Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer 2006, 6:237.
35. Saitoh Y, Kuratsu J, Takeshina H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 1995, 72:55-63.
36. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 2006, 25:2192-2202.

37. Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 2007, 26:6361-6371.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/132/prepub

doi:10.1186/1471-2407-10-132
Cite this article as: Bache et al.: Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer 2010 10:132.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit